These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 7532754

  • 21. Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries.
    Qureshi AA, Karpen CW, Qureshi N, Papasian CJ, Morrison DC, Folts JD.
    Lipids Health Dis; 2011 Apr 14; 10():58. PubMed ID: 21489303
    [Abstract] [Full Text] [Related]

  • 22. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries.
    Golino P, Buja LM, Ashton JH, Kulkarni P, Taylor A, Willerson JT.
    Circulation; 1988 Sep 14; 78(3):701-11. PubMed ID: 3409505
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D.
    Circulation; 1991 Mar 14; 83(3):1038-47. PubMed ID: 1900221
    [Abstract] [Full Text] [Related]

  • 26. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec 14; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 27. Combined effect of the 5-HT2 receptor antagonist DV-7028 and aspirin or heparin on coronary cyclic flow reductions in dogs.
    Tanaka T, Morishima Y, Watanabe K, Shibutani T, Yasuoka M, Shibano T.
    Cardiovasc Res; 1993 Jul 14; 27(7):1374-9. PubMed ID: 8252602
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
    de Clerck F, David JL, Janssen PA.
    Agents Actions; 1982 Jul 14; 12(3):388-97. PubMed ID: 6215842
    [Abstract] [Full Text] [Related]

  • 29. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct 14; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 30. Effects of 3-methoxycyproheptadine in a canine model of coronary thrombosis.
    Bush LR, Remy DC.
    J Pharmacol Exp Ther; 1988 Nov 14; 247(2):796-802. PubMed ID: 3183974
    [Abstract] [Full Text] [Related]

  • 31. Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys.
    Kawamura M, Tsuji N, Moriya N, Terashita Z.
    Thromb Res; 1997 May 15; 86(4):275-85. PubMed ID: 9187016
    [Abstract] [Full Text] [Related]

  • 32. The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis.
    Toomey JR, Samanen J, Valocik RE, Koster PF, Barone FC, Willette RN.
    Curr Drug Targets Cardiovasc Haematol Disord; 2002 Jun 15; 2(1):13-25. PubMed ID: 12769654
    [Abstract] [Full Text] [Related]

  • 33. The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.
    Stott DJ, Saniabadi AR, Hosie J, Lowe GD, Ball SG.
    Eur J Clin Pharmacol; 1988 Jun 15; 35(2):123-9. PubMed ID: 3142775
    [Abstract] [Full Text] [Related]

  • 34. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
    Berry CN, Lorrain J, Lochot S, Delahaye M, Lalé A, Savi P, Lechaire I, Ferrari P, Bernat A, Schaeffer P, Janiak P, Duval N, Grosset A, Herbert JM, O'Connor SE.
    Thromb Haemost; 2001 Mar 15; 85(3):521-8. PubMed ID: 11307825
    [Abstract] [Full Text] [Related]

  • 35. Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart.
    Mickelson JK, Simpson PJ, Lucchesi BR.
    J Mol Cell Cardiol; 1989 Apr 15; 21(4):393-405. PubMed ID: 2746660
    [Abstract] [Full Text] [Related]

  • 36. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U, Dörge L, Fischer S.
    Br J Pharmacol; 1996 May 15; 118(2):271-6. PubMed ID: 8735626
    [Abstract] [Full Text] [Related]

  • 37. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR.
    Circulation; 1991 Mar 15; 83(3):1048-56. PubMed ID: 1900222
    [Abstract] [Full Text] [Related]

  • 38. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD, Witzke C, Colon-Hernandez P, Guerrero JL, Bloch KD, Semigran MJ.
    J Am Coll Cardiol; 2006 Apr 04; 47(7):1471-7. PubMed ID: 16580539
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.